Metabolic dysfunction‐associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi‐centre cross‐sectional study
Main findingResult — go to the resultBeta coefficient (eGDR) −0.367 95% CI −0.472 to −0.261Authors' conclusion
In T1DM, MASLD was inversely associated with eGDR and biomarkers of insulin resistance but not with CGM-derived metrics.
Study context
- Population
- Adults with T1D undergoing vibration-controlled transient elastography (liver stiffness measurement (LSM) and controlled attenuation parameter (CAP)), all with a continuous glucose monitoring (CGM) device; mean age 56 years, mean BMI 26.0 ± 5.9 kg/m²consecutively enrolled
- Participants
- 198 adults
- Exposure
- MASLD vs no MASLD
- MASLDn = 73
- Outcome
- Prevalence of MASLD and significant liver fibrosis (LSM ≥ 7 kPa); association of MASLD with insulin sensitivity (eGDR) and CGM metrics
Methodological detailsmulti-centre, consecutive enrolment
- Multi-centre
- Consecutive enrolment
Main finding
As reported in the abstract
Beta coefficient (estimated glucose disposal rate (eGDR))
−0.367
95% CI −0.472 to −0.261
P < 0.001
- MASLD (using a CAP threshold of 274 dB/m)
- 73 (37%)
- Significant liver fibrosis among patients with MASLD
- 16 (8.1%)
- Mean eGDR, all patients
- 7.1 ± 2.3 mg/kg/min
Observational data: associations, not effects.
Further findings
Association of MASLD with CGM-derived metrics
- No association between MASLD and CGM-derived metrics
Sensitivity analysis: CAP threshold of 274 dB/m for MASLD
- Results were not different
Original publication
Metabolic dysfunction‐associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi‐centre cross‐sectional study. Diabetes Obes Metab. Published 13 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →